Hunter C. Smith - Director at Spyre Therapeutics, Inc.

Insider Transactions and Holdings

Role
Director
Issuer symbol
SYRE on Nasdaq
Identity 1 fact
Entity type
Individual
SEC evidence 1 fact
Source evidence
Open source filing history

There are no Buy or Sell transactions made by Hunter C. Smith since 01 Jun 2025

Holdings reported by Hunter C. Smith for Spyre Therapeutics, Inc.

Form 4 holding Director

Aeglea BioTherapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
1,950,000
Estimated value
Report date
22 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transactions reported by Hunter C. Smith for Spyre Therapeutics, Inc.

Sym Class Transaction % Reported value Reported price Shares Shares after Date Ownership
* indicates a reported price that failed the local validity check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .